Myriad Genetics News

Telecommunications and pharmaceuticals are the newcomers to the list of top five performing sectors this afternoon, with the telecommunication sector boosted by the fact that France Telecom is trading higher ...

Shares of Myriad Genetics Inc. fell 5 percent in Monday trading on news that the company's Act-Earli-AD trial, a pivotal 18-month Phase III study of Flurizan in patients with mild Alzheimer's disease , did not ...

Myriad Genetics is recently down $5.48 to $42.25 in pre-open trading. MYGN's Flurizan, a treatment for Alzheimer's diseases, had negative Phase 3 results.

I was really hoping that Flurizan would work, given the enormous amount of time and money invested in evaluating whether the drug could successfully inhibit the buildup of beta amyloid plaques in the brain ...

I was mentioning the gamma secretase enzyme around here just the other day as a longstanding target for Alzheimer's therapy.

Many Alzheimer's researchers deny that the failure of a promising remedy for the degenerative disease requires a return to the drawing board, saying the setback is not a death knell for drugs designed to target ...

Wachovia analyst Jonathan Feeney says, given Fortune Brands' new guidance, it looks like sales were slower than he thought, which was "clearly priced in." But he says he did not expect cost pressures from steel ...

Experimental Alzheimer's Drug Ineffective Glaucoma Could Blind 8.4 Million Asians by 2010 Here are some of the latest health and medical news developments, compiled by editors of HealthDay: The experimental ...

The biotechnology sector is seeing a nice boost today, making a surprising appearance in the top five performing sectors.

Citigroup Traders continue to nettle Citi stock with another 3% decline to $16.72. Over the weekend it was announced that Citi is overhauling its bonus system for senior management, making executive payouts ...

Myriad Genetics, Inc. today announced results of the Act-Earli-AD trial, an 18-month Phase 3 study of Flurizan in patients with mild Alzheimer's disease.

The Salt Lake City-based company said the 18-month study of Flurizan in patients with mild Alzheimer's disease "did not achieve statistical significance on either of its primary endpoints -- cognition and ...

H. Lundbeck A/S fell to the lowest level since 2004 in Copenhagen trading after an Alzheimer's treatment developed by the Nordic region's second-largest drugmaker and partner Myriad Genetics Inc .

There seem to be many reasonably priced plays within biotech at the present time, which is a very good thing in a soft market such as the one we have been slogging through.

News out of Dublin, Ireland-based drug company Elan early Tuesday reminded options traders with a flourish of the opportunities afforded by a drug breakthrough in the Alzheimer's space.

Sometimes, early stage data from a clinical trial can help inform investors about the prospects of a drug, and sometimes the data just makes a drug's future even harder to gauge.

First-to-market advantage among disease-modifying drugs combined with a positive safety profile, positions Flurizan to be received favorably among physicians and patients alike.

Main Category: Alzheimer's / Dementia Also Included In: Neurology / Neuroscience Article Date: 12 Jun 2008 - 6:00 PDT printer friendly view / write opinions rate article Myriad Genetics, Inc.

Shares of biotechnology company Myriad Genetics Inc. fell Wednesday on continued concern that the company's Alzheimer's disease drug candidate Flurizan could miss its goal in a late-stage study.

As research director of the Health Law Institute at the University of Alberta, he has heard this so often, he says, that he started to believe it too.